-
Alexion pulls Soliris vials on particle-contamination worriesAlexion ($ALXN) had to recall more vials of its rare-disease treatmentSolirisbecause particles were found in some of them. The move comes as Roche ($RHHBY) is reportedly eyeing a bid for the U.S.-base2013/8/21
-
Analyst to Merck: Get to work chopping costs, preferably $1B-plusWhen Merck cut its sales guidance last month, market-watchers predicted cost cuts. Soon, executives would be sharpening their scalpels--or heavier instruments--to compensate. After all, generic compet2013/8/20
-
CFDA Minister Zhang Yong meets Secretary for Food and Health of the Hong Kong SAR GovernmentOn the afternoon of August 12, 2013, Zhang Yong, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Dr. Ko Wing-man, Secretary for Food and Health of the Hong Kong S2013/8/20
-
NICE denies Pfizer lung cancer drug in final guidanceIn the past, the U.K.'s cost-effectiveness gatekeeper has shown that it will bend preliminary draft guidance decisions if the price is right. But for Pfizer ($PFE), which slashed costs on its targeted2013/8/19
-
Roche won't pursue Herceptin patents in IndiaRoche ($RHHBY) is throwing in the towel on its IP protection forHerceptininIndia. AsPharmAsia Newsreports, the company will give up its patents for Herceptin there, a move that opens it up to biosimil2013/8/19
-
South Africa's Adcock still in exclusive buyout talks with CFRSouth Africa's Adcock still in exclusive buyout talks with CFRSouth African drugmakerAdcock Ingramis so far staying true to suitorCFR Pharmaceuticals. Thursday, it said it remains in exclusive talks w2013/8/16
-
NY fund trustee to continue push for exec-pay clawbacks at AbbottNY fund trustee to continue push for exec-pay clawbacks at AbbottWhile other Big Pharma companies may have settled on clawback provisions for executive pay, hoping to inspire top management to toe the2013/8/16
-
China sales rep says Novartis ordered her to bribe doctorsChina sales rep says Novartis ordered her to bribe doctorsBig Pharma, beware of your former (and possibly current) employees inChina. Novartis ($NVS) is the latest drugmaker to be fingered forbriberyb2013/8/15
-
Boehringer sales tick upward 3% on big Pradaxa leapBoehringer sales tick upward 3% on big Pradaxa leapBoehringer Ingelheim's drugsPradaxaandTrajentaare both facing obstacles, but sales of both are still growing--and revenues for the company are growin2013/8/15
-
FDA: Infections prompt recall of all Specialty Compounding's sterile medsFDA: Infections prompt recall of all Specialty Compounding's sterile medsMore suspect drugs from a compounding pharmacy: The FDA says Specialty Compounding is yanking all of its sterile products after2013/8/14